In Figure 1 on page 1550 in the 4 April 2019 issue, in the dosage for prednisone under “Remission Induction (Course I),” “01-28” should read, “D 1-28.” The dosage for vincristine is missing under “Interim Maintenance (Course III).” Also, under “Delayed Intensification (Course IV),” the dosage for doxorubicin is missing and, in the dosage for vincristine, “D 1, 8, 43, and 50” should read, “D 1, 8, 15, 43, and 50.” The corrected Figure 1 and legend are shown below. The errors have been corrected in the online version of the article.
Treatment schema for CALGB 10403. *Maintenance therapy consisted of 12-week courses continuing until 3 years from initiation of interim maintenance for male and 2 years for female patients. Patients with precursor T-cell ALL received 24 Gy of prophylactic cranial irradiation during first cycle of maintenance therapy; those with CNS involvement at presentation received 18 Gy. 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; Ara-C, cytarabine; CTX, cyclophosphamide; DEX, dexamethasone; DOX, doxorubicin; DNR, daunorubicin; IT, intrathecally; MTX, methotrexate; PEG, pegylated asparaginase; PO, orally; pred, prednisone; VCR, vincristine.
Treatment schema for CALGB 10403. *Maintenance therapy consisted of 12-week courses continuing until 3 years from initiation of interim maintenance for male and 2 years for female patients. Patients with precursor T-cell ALL received 24 Gy of prophylactic cranial irradiation during first cycle of maintenance therapy; those with CNS involvement at presentation received 18 Gy. 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; Ara-C, cytarabine; CTX, cyclophosphamide; DEX, dexamethasone; DOX, doxorubicin; DNR, daunorubicin; IT, intrathecally; MTX, methotrexate; PEG, pegylated asparaginase; PO, orally; pred, prednisone; VCR, vincristine.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal